Evidence map›Paper›PMID 20635389›Full record

ArticleInternational journal of cancer2011

Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer.

Maria Notaridou, Lydia Quaye, Dimitra Dafou, Chris Jones, Honglin Song, Estrid Høgdall, Susanne K Kjaer, Lise Christensen, Claus Høgdall, Jan Blaakaer and 42 more

Open access · greenAbstract read
In one paragraph

Article in International journal of cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
8.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 67 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Mutant cohesin in premature ovarian failure.The New England journal of medicine · 2014
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

52 authors at 20 institutions in 6 countries.

Maria NotaridouGynaecological Oncology Unit, UCL EGA Institute for Women's Health, University College London, United Kingdom.
Lydia Quaye
Dimitra Dafou
Chris Jones
Honglin Song
Estrid Høgdall
Susanne K Kjaer
Lise Christensen
Claus Høgdall
Jan Blaakaer
Valerie McGuire
Anna H Wu
David J Van Den Berg
Malcolm C Pike
Aleksandra Gentry-Maharaj
Eva Wozniak
Tanya Sher
Ian J Jacobs
Jonathan Tyrer
Joellen M Schildkraut
Patricia G Moorman
Edwin S Iversen
Anna Jakubowska
Krzysztof Mędrek
Jan Lubiński
Roberta B Ness
Kirsten B Moysich
Galina Lurie
Lynne R Wilkens
Michael E Carney
Shan Wang-Gohrke
Jennifer A Doherty
Mary Anne Rossing
Matthias W Beckmann
Falk C Thiel
Arif B Ekici
Xiaoqing Chen
Jonathan Beesley
Australian Ovarian Cancer Study Group/Australian Cancer Study (Ovarian Cancer)
Jacek Gronwald
Peter A Fasching
Jenny Chang-Claude
Marc T Goodman
Georgia Chenevix-Trench
Andrew Berchuck
C Leigh Pearce
Alice S Whittemore
Usha Menon
Paul D P Pharoah
Simon A Gayther
Susan J Ramus
Ovarian Cancer Association Consortium
University College London · GBUniversity of Hawaiʻi at Mānoa · USUniversity of Southern California · USQIMR Berghofer Medical Research Institute · AUUniversity of Cambridge · GBDuke Medical Center · USInternational Hereditary Cancer Center · PLDanish Cancer Society · DKFred Hutch Cancer Center · USUniversitätsklinikum Erlangen · DEUniversity of California, Los Angeles · USUniversity of Copenhagen · DKZero to Three · USAarhus University Hospital · DKBecton Dickinson (United States) · USFriedrich-Alexander-Universität Erlangen-Nürnberg · DEGuy's Hospital · GBRoswell Park Comprehensive Cancer Center · USStanford University · USThe University of Texas Health Science Center at Houston · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6M
GENETIC SUSCEPTIBILITY TO CANCER IN MULTIETHNIC COHORTSR01CA063464 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HENDERSON, BRIAN E · 2001 to 2005
$23.2M
USC CANCER EPIDEMIOLOGY &BIOSTATISTICS UNITP01CA017054 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI DEAPEN, DENNIS M. · 1985 to 2009
$18.2M
COLLABORATIVE STUDY OF OVARIAN CANCER IN TWO RISK GROUPSR01CA058598 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI GOODMAN, MARC T · 1993 to 2012
$4.6M
Epidemiology of Ovarian Cancer:New HypothesesR01CA087538 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ROSSING, MARY ANNE · 2002 to 2006
$3.5M
Inflammation and Ovarian CancerR01CA095023 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BUNKER, CLAREANN H. · 2003 to 2008
$2.7M
SURVEILLANCE EPIDEMIOLOGY &END RESULTS PROGRAMN01PC067010 · PC · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ROSS, RONALD K · 1996 to 2000
$2.4M
GENETIC SUSCEPTIBILITY TO CANCER IN MULTIETHNIC COHORTSU01CA063464 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HENDERSON, BRIAN E · 1996 to 2000
$943k
OVARIAN CANCER RISK AND SURVIVAL IN BRCA CARRIERSK07CA080668 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MODUGNO, FRANCESMARY · 2000 to 2005
$661k
The Progesterone Receptor Gene and Ovarian Cancer RiskR03CA113148 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI PEARCE, CELESTE LEIGH · 2004 to 2005
$163k
CASE-CONTROL STUDY OF OVARIAN CANCER IN LOS ANGELESR01CA061132 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI PIKE, MALCOLM C · 1993 to 1997
–
Cancer Research UK 10119Cancer Research UK 10124Cancer Research UK 11021Cancer Research UK A10119Cancer Research UK A10124Cancer Research UK C8804/A7058Medical Research Council G0801875NCI NIH HHS CA14089NCI NIH HHS CA16056NCI NIH HHS CA17054NCI NIH HHS CA61132NCI NIH HHS CA63464NCI NIH HHS CA71766NCI NIH HHS K07 CA080668NCI NIH HHS K07-CA80668NCI NIH HHS N01-CN67001NCI NIH HHS N01 PC035137NCI NIH HHS N01-PC-035137NCI NIH HHS N01 PC067010NCI NIH HHS P01 CA017054NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA016056NCI NIH HHS R01 CA058598NCI NIH HHS R01 CA063464NCI NIH HHS R01 CA087538NCI NIH HHS R01 CA095023NCI NIH HHS R01CA095023NCI NIH HHS R01-CA-58598NCI NIH HHS R01 CA61107NCI NIH HHS R01 CA87538NCI NIH HHS R03 CA113148NCI NIH HHS R03-CA113148NCI NIH HHS U01 CA063464
6 · The paper itself

Abstract

Common germline genetic variation in the population is associated with susceptibility to epithelial ovarian cancer. Microcell-mediated chromosome transfer and expression microarray analysis identified nine genes associated with functional suppression of tumorogenicity in ovarian cancer cell lines; AIFM2, AKTIP, AXIN2, CASP5, FILIP1L, RBBP8, RGC32, RUVBL1 and STAG3. Sixty-three tagging single nucleotide polymorphisms (tSNPs) in these genes were genotyped in 1,799 invasive ovarian cancer cases and 3,045 controls to look for associations with disease risk. Two SNPs in RUVBL1, rs13063604 and rs7650365, were associated with increased risk of serous ovarian cancer [HetOR = 1.42 (1.15-1.74) and the HomOR = 1.63 (1.10-1.42), p-trend = 0.0002] and [HetOR = 0.97 (0.80-1.17), HomOR = 0.74 (0.58-0.93), p-trend = 0.009], respectively. We genotyped rs13063604 and rs7650365 in an additional 4,590 cases and 6,031 controls from ten sites from the United States, Europe and Australia; however, neither SNP was significant in Stage 2. We also evaluated the potential role of tSNPs in these nine genes in ovarian cancer development by testing for allele-specific loss of heterozygosity (LOH) in 286 primary ovarian tumours. We found frequent LOH for tSNPs in AXIN2, AKTIP and RGC32 (64, 46 and 34%, respectively) and one SNP, rs1637001, in STAG3 showed significant allele-specific LOH with loss of the common allele in 94% of informative tumours (p = 0.015). Array comparative genomic hybridisation indicated that this nonrandom allelic imbalance was due to amplification of the rare allele. In conclusion, we show evidence for the involvement of a common allele of STAG3 in the development of epithelial ovarian cancer.

Indexed as

AllelesCell Cycle ProteinsFemaleGenetic Predisposition to DiseaseHumansLoss of HeterozygosityNeoplasms, Glandular and EpithelialNuclear ProteinsOligonucleotide Array Sequence AnalysisOvarian NeoplasmsPolymorphism, Single NucleotideRisk FactorsCell Cycle ProteinsNuclear ProteinsSTAG3 protein, human

Identifiers

PMID20635389
PMCPMC3098608
OpenAlexW1986907906

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.